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A B S T R A C T
Objectives: We assessed C-reactive protein (CRP) and plasma albumin (PA) kinetics to evaluate
community-acquired bloodstream infection (CA-BSI) patients’ 1-year outcomes.
Methods: Population-based study, with CRP and PA measurements on day 1 (D1) and D4. Relative CRP
variations in relation to D1 CRP value were evaluated (CRP-ratio). Patients were classified as fast
response, slow response, non-response, and biphasic response.
Results: A total of 935 patients were included. At D4, the CRP-ratio was lower in survivors on D365 in
comparison with D4–D30 non-survivors and D30–D365 non-survivors (p < 0.001). In comparison with
fast response patients, non-response and biphasic response patients had 2.74 and 5.29 increased risk,
respectively, of death in D4–D30 and 2.77 and 3.16 increased risk, respectively, of death in D31–D365. PA
levels remained roughly unchanged from D1–D4, but lower D1 PA predicted higher short and long-term
mortality (p < 0.001). The discriminative performance of the CRP-ratio and D1 PA to identify patients with
poor short and long-term mortality after adjustments was acceptable (AUROC = 0.79).
Conclusions: Serial CRP measurements at D1 and D4 after CA-BSI is clinically useful to identify patients
with poor outcome. Individual patterns of CRP-ratio response with PA at D1 further refine our ability of
predicting short or long-term mortality.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Community-acquired bloodstream infection (CA-BSI) is a well-
defined infectious clinical entity that is associated with high
morbidity and mortality, particularly in patients with previous
comorbidities (Gradel et al., 2013). In addition, CA-BSI outcome
depends markedly on the timing and adequacy of empiric
antibiotic therapy (Póvoa et al., 2005b; Kumar, 2014).* Corresponding author at: Center for Clinical Epidemiology, Odense University
Hospital, and Research Unit of Clinical Epidemiology, Institute of Clinical Research,
University of Southern Denmark, Kløvervænget 30, Entrance 216, Ground Floor,
5000 Odense C, Denmark.
E-mail address: kim.gradel@rsyd.dk (K.O. Gradel).
https://doi.org/10.1016/j.ijid.2020.03.063
1201-9712/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The diagnosis of CA-BSI is based on a combination of clinical,
laboratory and microbiology criteria (Gross et al., 1994). Currently,
the assessment of patient response to antibiotic therapy relies on
the resolution of the same criteria as used for diagnosis, e.g. fever
and leukocytosis, which are very unspecific and also poorly
sensitive (Halm et al., 1998; Kaukonen et al., 2018). To overcome
these limitations, clinicians frequently use biomarker kinetics, in
particular C-reactive protein (CRP) and procalcitonin (Póvoa et al.,
2011, 2016).
For 47 ventilator-associated pneumonia patients and 44 CA-BSI
patients, we found that the patterns of CRP-ratio response to
antibiotic therapy were markedly associated with mortality and
clinical course, as early as day 4 (Póvoa et al., 2005a, 2005b). But its
impact on long-term outcomes has never been evaluated.
We have previously shown that plasma albumin (PA) decreases
significantly just before the CA-BSI diagnosis (Gradel et al., 2018b).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Derivation of the study cohort.
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studied in the assessment of CA-BSI response to antibiotic therapy.
The Danish Observational Registry of Infectious Syndromes
(DORIS) is a population-based research database comprising a high
number of CA-BSI patients as well as their data before and after the
reference CA-BSI episode, namely biochemistry and microbiologic
data (Gradel et al., 2013, 2018b).
This gave us the opportunity to assess CRP and PA kinetics in
response to antibiotic therapy in order to identify patients’
outcomes, and to validate the concept of patterns of CRP-ratio
response to antibiotics.
Materials and methods
Setting
The Danish national health system, covering both primary and
hospital care, is tax financed and consequently free of charge for
the individual patient. All residents have a unique civil registration
number used for all health contacts and linkage between health
administrative registries (Schmidt et al., 2014). The admission of all
residents with acute illnesses from a well-defined geographical
region to a hospital prompted a population-based study based on
data from registries (vital status, diagnoses, laboratory data) and
the medical records (sepsis severity and CNS dysfunction on
admission) in the DORIS research database (Gradel et al., 2013,
2018b). Sepsis was categorized as severe sepsis/septic shock if
organ dysfunction or hypotension (systolic blood pressure
<90 mmHg) occurred. Because data on hypoperfusion were not
valid we did not distinguish between severe sepsis and septic
shock (Gradel et al., 2013).
Study cohort
The DORIS research database has been described in detail
elsewhere (Gradel et al., 2013). In brief, it comprised all adults (>14
y) residing in Funen County with a first episode of CA-BSI, in the
period 2000–2008, a total of N = 2785 patients. For the present
study, the cohort comprised the 2418 patients with 1 measure-
ment of CRP and PA on the same day within a time period from 30
days before through 30 days after the CA-BSI date (Gradel et al.,
2018b). A CA-BSI was defined as BSI occurring <3 days after
hospital admission and without inpatient contact in the preceding
7 days. We had all the CA-BSI patients’ CRP and PA measurements
from 2000 through 2010 (Gradel et al., 2018b). Patients with
unrealistically low levels of PA (<11 g/L) at the day of the CA-BSI
diagnosis were excluded (N = 3, 0.12%). The CRP values below the
limit of detection (<10 mg/L in 2000–2003, N = 324 [2.0%]; <5 mg/L
in 2004–2009, N = 259 [1.6%]) were randomly allocated a value in
the range 0–9 mg/L (for CRP <10 mg/L) or 0–4 mg/L (for CRP <5 mg/
L), as described elsewhere (Gradel et al., 2018b).
We refer to Figure 1 for derivation of the study cohort. To
capture the most relevant measurement, we initially retrieved the
highest CRP and the lowest PA value within the first 24 h of the CA-
BSI diagnosis date (designated D1). The cohort of the present study
comprised 935 patients alive on D4 with CRP/PA measured on D1
and on D4, their CRP on D1 was >50 mg/L (Chan et al., 2004; Gaini
et al., 2006; Knudtzen et al., 2014), and their vital status could be
assessed as from D1.
Analyses of CRP and PA levels
All analyses were performed by the Department of Clinical
Biochemistry and Pharmacology, Odense University Hospital
(OUH) and results were recorded in the Netlab (Medasys S.A.,
Littau, Switzerland) database. Both CRP and PA were measured onModular P1 (Roche, Mannheim, Germany), CRP using an immune-
turbidimetric principle and PA by use of a bromocresol green dye-
binding method. All specimen dates refer to date of draw of blood
specimens.
Definitions
Due to the biological properties of CRP (Vigushin et al., 1993;
Póvoa, 2002), we assessed the relative CRP variations (CRP-ratio).
The CRP-ratio was calculated on D4 in relation to the CRP value on
D1.
Patients were classified according to an individual pattern,
previously defined (Póvoa et al., 2005a), of a CRP-ratio response to
antibiotic therapy: fast response – when the CRP-ratio at D4 was
<0.4 of the D1 CRP; slow response – characterized by a continuous,
but slow, decrease of the CRP-ratio, which was 0.4 and <0.8 on
D4; non-response – when the CRP-ratio always remained 0.8 of
the D1 value; biphasic response – characterized by an initial CRP-
ratio decrease to levels <0.8 of the D1 CRP, followed by a secondary
rise to values 0.8.
For PA, no individual patterns after an infection have to our
knowledge been reported in the literature. Because the one-time
level of PA on D1 was a strong prognostic mortality predictor in our
study cohort (Magnussen et al., 2016) we incorporated this in the
model.
Statistical analysis
Initially, we computed contingency tables with categorical and
continuous variables of baseline characteristics.
We determined two outcomes, D4–D30 (short term) and D31–
D365 (long term) mortality.
Box plots of CRP and PA were computed on D1, D2, D3, and D4 in
relation to whether patients died on D4–D30, died on D31–D365,
or were alive on D365 (excluding patients censored before D365 as
their results were insignificantly different from patients alive on
D365). We performed a nonparametric test for trend across
ordered groups (Cuzick, 1985) for the three patients groups in
relation to their mean CRP and PA levels on each of the days D1, D2,
D3, and D4. We reiterated the box plots by computing ratios on D2,
D3, and D4 in comparison to D1 and performed linear regression
analyses to deduce whether the ratios differed from D1.
We further computed Kaplan–Meier curves covering D4–D365,
of the four CRP-ratio response patterns and PA quartiles on D1 and
used the log-rank test to assess whether the curves differed.
The differences between hazard ratios in Cox proportional
hazards regression analyses and odds ratios (ORs) in logistic
regression analyses were insignificant as there was almost
complete follow-up (data not shown). Hence, we applied the
latter, with D4–D30 and D31–D365 mortality as outcomes, as this
enabled the subsequent computation of receiver operating
characteristic (ROC) curves and the area under these (AUROC).
Initially, we performed three models, one with the four CRP-ratio
response patterns, one with PA on D1, and one in which the CRP-
ratio response patterns were combined with PA on D1. We
reiterated these models by the amendment of gender, age, the
Charlson comorbidity index (0, 1–2, >2 points) (Charlson et al.,
1987), the main bacterial groups (mono-microbial Gram-positive,
mono-microbial Gram-negative, poly-microbial), and number of
organ dysfunctions (0, 1, >1). For all models, we reported ORs and
AUROCs with 95% confidence intervals (CIs) and we evaluated
whether AUROCs differed significantly from each other (DeLong
et al., 1988).
All two-sided p-values <0.05 were considered significant.
The Stata software (v.14.2, StataCorp, TX, USA) was used for all
analyses.
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Baseline characteristics
The baseline clinical characteristics at the day of CA-BSI
diagnosis are presented in Table 1. At CA-BSI diagnosis, 18.8%
presented with sepsis, 58.7% with severe sepsis or septic shock,
and 65.0% with one or more organ dysfunctions. A number of 147
(15.7%) and 197 (21.1%) patients died on D4–D30 and D31–D365,
respectively, whereas 60 (6.4%) patients with their CA-BSI between
31 May 2008 and 31 December 2008 were censored before D365 as
they were alive on the latest vital status date (31 May 2009).
Kinetics of CRP levels
Regardless of patient group (alive on D365, dead D4–D30, dead
D31–D365), CRP levels decreased from D1 to D4 and they were
significantly lower on D3 and D4 in comparison to D1 (all p  0.01)
(Figure 2, upper panel). There were no differences between the
three patients’ groups on D1 (p = 0.23) or D2 (p = 0.39). On D3 and
D4, the CRP levels differed significantly; survivors on D365
presented the lowest CRP levels followed by D31–D365 non-
survivors, with the highest levels in D4–D30 non-survivors
(p  0.01). Patients censored before D365, all of whom were aliveTable 1
Baseline patient characteristics (n = 935).
Text Number (%)a
Age, years
Mean, SD 66.7, 15.9
Females 429 (45.9)
Charlson comorbidity index
0 points 194 (20.8)
1–2 points 396 (42.4)
>2 points 345 (36.9)
Sepsis severity
No sepsis 35 (3.7)
Possibly sepsis 116 (12.4)
Sepsis 176 (18.8)
Severe sepsis or septic shock 549 (58.7)
Organ dysfunction without sepsis 59 (6.3)
Number of organ dysfunctions
0 327 (34.9)
1 337 (36.0)
2 271 (29.0)
Microbiological isolates
Mono-microbial Gram-positive 365 (39.0)
Staphylococcus aureus 150 (16.0)
Streptococcus pneumoniae 126 (13.5)
Streptococci, other 66 (7.1)
Enterococcus faecalis 23 (2.5)
Mono-microbial Gram-negative 474 (50.7)
Escherichia coli 327 (35.0)
Klebsiella spp. 37 (4.0)
Pseudomonas aeruginosa 34 (3.6)
Other 76 (8.1)
Poly-microbial 96 (10.3)
Vital status data
Dead day 4–30 147 (15.7)
Dead day 31–365 197 (21.1)
Alive on day 365 531 (56.8)
Censored before day 365b 60 (6.4)
Admitted to, on day of CA-BSI
Surgery 97 (10.4)
Medical 651 (69.6)
Intensive care unit 58 (6.2)
Oncology/hematology 123 (13.2)
Unknown 6 (0.6)
a Except for “age, years”, cf. text.
b All alive on day 154.SD, standard deviation; CA-BSI, community-acquired
bloodstream infection.at least 154 days after their CA-BSI, did not differ from patients
alive on D365 (data not shown).
Kinetics of PA levels
PA levels did not differ on D2, D3, or D4 in comparison to D1 (all
p  0.29) (Figure 2, lower panel). They rose slightly on D4, except
for patients dying on D4–D30, which was unchanged in compari-
son to D3 levels. On all days, there were clear trends of decreasing
PA levels over the three patient groups (p < 104). Patients
censored before D365 did not differ from patients alive on D365
(data not shown).
Mortality characteristics in relation to CRP-ratio response patterns
and PA quartiles on D1
Among the 342 patients with a fast CRP-ratio pattern, 222
(64.9%) were alive on D365 (Table 2). The percentage of patients
alive on D365 declined over slow response, non-response, and bi-
phasic response patterns (55.3%, 41.5%, and 39.7%, respectively).
There was no clear trend for death in D31–D365 or for patients
censored before D365, whereas a clear increasing trend was seen
for death in D4–D30, from 10.2% in the fast CRP-ratio pattern to
33.3% in the biphasic CRP-ratio pattern.
For PA quartiles on D1, an increasing percentage was alive on
D365 as the quartile increased (from 42.7% in the lowest to 70.1% in
the highest quartile, Table 2). It was especially deaths on D4–D30
that contributed to this, especially in the two lower quartiles
where 20.4% and 28.6% died, in contrast to the two higher quartiles
(PA 30 g/L) where no more than 10.6% died.
Kaplan–Meier mortality curves
The increasing mortality from fast response, over slow
response, non-response, and biphasic response, as depicted in
Table 2, was confirmed in the Kaplan–Meier mortality curves
(Figure 3, upper panel). Likewise, the higher mortality parallel to
lower PA quartile on D1 was seen (Figure 3, lower panel).
Logistic regression analyses
For both D4–D30 and D31–D365 mortality, ORs (95% CIs) in the
unadjusted and adjusted models did not differ materially (Table 3).
Likewise, the ORs of the patterns of CRP-ratio responses or PA on
D1 changed little when both of these were included in the models.
The CRP-ratio response pattern showed a clear trend of increasing
ORs from fast to biphasic response for both mortality outcomes.
For PA on D1 with D4–D30 mortality as the outcome, the OR was
0.90, whereas it was 0.94 (adjusted) or 0.95 (unadjusted) with
D31–D365 mortality as the outcome.
AUROCs for the logistic regression models
Regardless of outcome, the CRP-ratio response patterns
contributed relatively little to the AUROC (0.61 for D4–D30 and
0.57 for D31–D365 mortality) (Table 4). PA on D1 rendered an
AUROC of 0.70 for the D4–D30 mortality, whereas its AUROC of
0.59 contributed less to the prediction of D31–D365 mortality. The
combination of the CRP-ratio response pattern and PA on D1
increased the AUROCs 0.04 in comparison to the models with only
PA on D1. The amendment of covariates in the full model (age,
gender, comorbidity, bacteria, number of organ dysfunctions)
increased the AUROCs by 0.05–0.15, with the highest AUROC of
0.79 for the complete model with the D4–D30 mortality as
outcome.
Figure 2. Box plots of C-reactive protein (CRP) and plasma albumin (PA) on day 1, 2, 3, and 4, for patients alive on day 365, dead in day 31–365, and dead in day 4–30. Absolute
levels in the left column and ratios in relation to day 1 in the right column. For ratios, median levels are shown in the top. For CRP ratios, a horizontal line is depicted for 0.4 and
0.8.
Table 2
Mortality in relation to C-reactive protein (CRP) ratio response pattern and plasma albumin quartile on day 1.
Text Total Alive on day 365 Censored before day 365 Dead day 31–365 Dead day 4–30
CRP-ratio response pattern
Fast response 342 222 (64.9) 24 (7.0) 61 (17.8) 35 (10.2)
Slow response 465 257 (55.3) 27 (5.8) 104 (22.4) 77 (16.6)
Non-response 65 27 (41.5) 7 (10.8) 17 (26.2) 14 (21.5)
Biphasic response 63 25 (39.7) 2 (3.2) 15 (23.8) 21 (33.3)
Plasma albumin quartile on D1
11–24 g/L 206 88 (42.7) 8 (3.9) 51 (24.8) 59 (28.6)
25–29 g/L 216 112 (51.9) 15 (6.9) 45 (20.8) 44 (20.4)
30–33 g/L 235 136 (57.9) 17 (7.2) 57 (24.3) 25 (10.6)
34–46 g/L 278 195 (70.1) 20 (7.2) 44 (15.8) 19 (6.8)
Total 935 531 (56.8) 60 (6.4) 197 (21.1) 147 (15.7)
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In the present study we evaluated the short and long-term
mortality in a large cohort of CA-BSI patients, as assessed by serial
measurements of CRP and PA. In patients alive on D4 we found that
the absolute and relative changes of CRP were markedly higher in
survivors and the identification of the individual CRP-ratio pattern
of response was independently associated both with D4–D30 and
D31–D365 mortality. In addition, we found that lower PA on D1
independently predicted higher D4–D30 and D31–D365 mortality.
There are several studies that assess the clinical response by
evaluating the course of CRP after prescription of antibiotics (Póvoa
et al., 2005a, 2005b; Coelho et al., 2007; Bruns et al., 2008; Lisboaet al., 2008; Moreno et al., 2010; Póvoa et al., 2011, 2017).
Altogether, survivors present a D3/D4 CRP around 60% of the initial
value, whereas it remains roughly unchanged in non-survivors.
However, concerning BSI the evaluation of CRP kinetics has only
been done previously in a pilot study with a small sample size
(N = 44) (Póvoa et al., 2005b).
In our study, with a much larger cohort of BSI (N = 935), all
community-acquired, CRP (absolute and relative changes) pre-
sented the same course. Among patients alive on D4, those with
good short and long-term mortality was just below 46% of the D1
level whereas it was 58% for those dying up to D30 (AUROC = 0.61).
We subsequently classified our patients according to the
individual patterns of CRP-ratio response as published elsewhere
Figure 3. Kaplan–Meier mortality curves for C-reactive protein (CRP) ratio response patterns (upper panel) and quartiles of plasma albumin on day 1 (lower panel).
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infections and clinical settings, have assessed the prognostic value
of individual patterns of CRP-ratio response to antibiotic therapy
(Póvoa et al., 2005a, 2005b; Coelho et al., 2007; Moreno et al., 2010;
Póvoa et al., 2011, 2017; Rabello et al., 2017). In all these studies,
patients with a fast response pattern had much lower hospital
mortality than those presenting with non-response or a biphasic
response. But none of those studies assessed the impact of CRP-
ratio patterns on long-term mortality.In the present study we found that among patients alive on
D4 the patterns of CRP-ratio response were associated with
both short and long-term mortality, even after adjusting for
clinically important confounders (Table 3). In comparison
with those having a fast response pattern, patients with a
non-response or a biphasic response patterns had a 2.5 and
5.0 increased risk, respectively, of death in D4–D30 and
a 2.5 and 3.0 increased risk, respectively, of death in
D31–D365.
Table 3
Logistic regression analyses.
Model 4–30 day mortality 31–365 day mortality
Unadjusted Adjusteda Unadjusted Adjusteda
C-reactive protein ratio response
Fast 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Slow 1.74 (1.14–2.67)b 1.75 (1.13–2.73) 1.47 (1.02–2.12)b 1.45 (0.98–2.13)
None 2.41 (1.21–4.79) 2.74 (1.32–5.68) 2.29 (1.17–4.48) 2.77 (1.34–5.74)
Biphasic 4.39 (2.34–8.23) 5.29 (2.67–10.5) 2.18 (1.08–4.40) 3.16 (1.46–6.84)
Plasma albumin on D1 0.90 (0.87–0.92) 0.90 (0.87–0.92) 0.95 (0.93–0.98) 0.94 (0.92–0.97)
C-reactive protein ratio response
Fast 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Slow 1.71 (1.10–2.65) 1.68 (1.06–2.64) 1.50 (1.04–2.17) 1.46 (0.99–2.16)
None 3.22 (1.56–6.67) 3.00 (1.40–6.41) 2.55 (1.29–5.07) 2.90 (1.38–6.08)
Biphasic 3.56 (1.84–6.92) 4.29 (2.11–8.71) 2.06 (1.00–4.18) 2.95 (1.35–6.45)
Plasma albumin on D1 0.90 (0.87–0.93) 0.90 (0.87–0.93) 0.95 (0.93–0.98) 0.95 (0.92–0.97)
a Adjusted for gender, age, the Charlson comorbidity index (0, 1–2, >2 points), the main bacterial groups (mono-microbial gram-positive, mono-microbial gram-negative,
poly-microbial), and number of organ dysfunctions (0, 1, >1).
b Odds ratio (95% confidence interval).
Table 4
Discrimination analyses, based on the logistic regression analyses.
Model AUROC (95% CI)a
4–30 day mortality 31–365 day mortality
(1) C-reactive protein ratio response 0.61 (0.56–0.65)A 0.57 (0.53–0.61)A
(2) C-reactive protein ratio response, full modelb 0.73 (0.69–0.77)BCD 0.72 (0.68–0.76)B
(3) Plasma albumin on day 1 0.70 (0.65–0.74)C 0.59 (0.55–0.64)A
(4) Plasma albumin on day 1, full model 0.77 (0.73–0.81)D 0.72 (0.68–0.76)B
(1) +3 0.74 (0.69–0.78)BD 0.63 (0.58–0.67)C
(2) +3 0.79 (0.75–0.82)E 0.74 (0.70–0.78)B
a Area under the receiver operating characteristic curve (95% confidence interval).
b The full model amends the following covariates: gender, age, the Charlson comorbidity index (0, 1–2, >2 points), the main bacterial groups (mono-microbial gram-
positive, mono-microbial gram-negative, poly-microbial), and number of organ dysfunctions (0, 1, >1).Upper case letters: AUROC for models are significantly different
(p < 0.05) if letters are different.
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persistent low-grade inflammation, assessed by elevations in
circulating interleukin (IL) 6, IL-10, or CRP at the time of hospital
discharge are associated with worse long-term outcomes (Kellum
et al., 2007; Yende et al., 2008, 2014, 2019). The results of our study
go somewhat beyond that as we show that a persistent
inflammation measured as early as D4, assessed by CRP-ratio, is
strongly correlated with both short and long term mortality.
The biological properties of PA differ from those of CRP, such as
less variation in levels and a half-life of about 20 days (Franch-
Arcas, 2001), in contrast to 19–20 h for CRP (Vigushin et al., 1993).
As a result, the absence of marked changes of PA levels till D4 was
an expected result. Similarly, it was not feasible to extrapolate the
above four CRP-ratio response patterns to PA. Preliminarily, we
derived a PA pattern based on only decreases, only increases, or
both, between D1–D4, but these had no prognostic prediction,
especially not when PA on D1 was incorporated in the models (data
not shown).
The strong prognostic prediction of a bad outcome, both
mortality and morbidity, in relation to a lower PA level is well-
known (Vincent et al., 2003; Levitt and Levitt, 2016). In the present
study, we divided patients in quartiles of PA on D1 and besides
showing an impact on the D4–D30 mortality, this effect also had
marked influence on the long-term mortality.
Finally, we assessed the ability of the CRP-ratio and PA on D1 to
identify patients with poor short and long-term mortality. After
adjusting for gender, age, Charlson comorbidity index, the main
bacterial groups, and number of organ dysfunctions, the complete
model presented an acceptable discriminative performance with
an AUROC of 0.79 (Hosmer and Lemeshow, 2000).To our knowledge, our study is the first to have combined CRP
and PA as prognostic predictors in BSI patients. The combined use
of CRP and PA has shown in numerous publications to be good a
predictor of cancer-related mortality. Especially the Glasgow
Prognostic Score (reviewed in McMillan, 2013) and the CRP/PA
ratio (reviewed in Xu et al., 2017) have gained momentum. A few
studies have combined CRP and PA as prognostic predictors in
patients that may resemble BSI patients more than cancer patients.
For 334 patients admitted to an ICU with sepsis or septic shock,
Ranzani et al. showed that the CRP/PA ratio at admission or
discharge predicted 90-day mortality (Ranzani et al., 2013). In 424
CA pneumonia patients, the amendment of initial CRP and PA
levels to the pneumonia severity index improved the predictability
of 28-day mortality, with an AUROC of 0.81, similar to our full
model (Lee et al., 2011).
Our study has several strengths. To the best of our knowledge
this is the study with the largest sample size of CA-BSI patients
assessing serial measurements of CRP and PA. Secondly, our study
is population-based and included clinically important data for
comorbidity as well as the patients’ septic conditions and vital
organ dysfunctions around the time of the CA-BSI episode. And
finally, for the first time the impact of the CRP-ratio patterns on the
long-term mortality was assessed.
There are also several limitations that should be acknowledged.
Firstly, it is a retrospective study although the data per se were
prospectively collected from registries and medical records.
Secondly, we had no information about the nutritional status. This
is a concern in relation to whether PA is mainly a nutritional or
inflammatory marker. Most reviews, including recent ones, imply
that PA is a poor nutritional marker (Fuhrman, 2002; Lee et al., 2015;
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around the CA-BSI as well as the high inverse correlation with the
CRP level as seen in our study cohort (Gradel et al., 2018b) indicate
that hypoalbuminemia is mainly an inflammatory marker. Thirdly,
although we had microbiology results, we had no antibiotic
sensitivity tests. As a result, we cannot evaluate the adequacy of
empiric antibiotic therapy. Fourthly, we had no data on fluid therapy
and fluid balance, including whether it contained albumin or
plasma. However, neither albumin nor plasma are standard
treatments to sepsis of BSI patients in OUH and our data on
albumin vs. hemoglobin levels around the time of CA-BSI indicate
that such data would not alter the interpretation of the results
(Gradel et al., 2018b). Fifthly, roughly 50% of the CA-BSI patients
were excluded from our study for three main reasons that impede
the calculation of the D4 CRP-ratio; the CRP was not measured on D1
and D4, death occurred before D4, and the CRP levels were low on
D1. The lack of data is a well-recognized limitation of studies using
real-life data. Different patients present different numbers of
specimens and highly variable time intervals between specimens.
However, we have shown that the trajectories of CRP and PA levels
around the CA-BSI (between day 30 and day 30) did not differ in
relation to the number of specimens from each patient (Gradel et al.,
2018a). Therefore, this would enable us to perform longitudinal
analyses of real-life data in our population-based database. For the
same reason, we could not also calculate CRP-ratio for patients who
died before D4. We do know, however, that the mortality of BSI
patients with high initial CRP levels is significantly higher (Gradel
et al., 2011). Another important characteristic of a biomarker for
longitudinal evaluation is amplitude of variation. If the values are
very low or within “normal” range on D1, it is not possible to assess
changes over time since some variations could be the result of the
within-patient variation related to the measurement methodology
(Póvoa et al., 2015). Sixthly, according to the CRP-ratio patterns of
response, at least three measurements are needed to classify a
biphasic pattern. As a result, patients with only two measurements
could have been misclassified. However, the D4 CRP-ratio is above
80% in both a biphasic and a non-response pattern and both were
associated with a poor prognosis (Póvoa et al., 2005a, 2005b, 2017).
Finally, some of our CA-BSIs are healthcare-associated according to
widely accepted definitions (Friedman et al., 2002) but we believe
this has little impact on the patho-physiological properties of the
studied biomarkers.
Conclusion
Serial CRP measurements after CA-BSI diagnosis are clinically
useful as early as D4 to identify patients with a poor outcome.
Besides, the identification of individual pattern of CRP-ratio
response further refines our ability of prognostication either of
short or long-term mortality. The addition of D1 PA further
increases this ability. Patterns associated with persistent inflam-
mation are associated with a higher short or long-term mortality.
Taken together these results confirm that serial measurements
of biomarkers, like CRP, could be used not only for prognostication
but also in antimicrobial stewardship programs (Borges et al.,
2019), but further studies are needed.
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